Amido spirocyclic amide and sulfonamide derivatives
Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
1. A process of preparing a compound of Formula I:
wherein:
R is (a) an 8-, 9-, or 10-membered bicyclic heteroaryl comprising one heteroatom selected from N, S, and O, and one, two, or three additional N atoms, wherein said bicyclic heteroaryl is unsubstituted or is substituted with one or more substituents selected from the group consisting of deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl, and alkoxy, and wherein one or more N atoms of said bicyclic heteroaryl is optionally an N-oxide; or
(b) a five- or six-membered nitrogen-linked heterocycloalkyl ring fused to a phenyl or monocyclic five- or six-membered heteroaryl, wherein said phenyl or heteroaryl is unsubstituted or is substituted with one or more substituents selected from the group consisting of deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl, and alkoxy; and
R 1 is H, —(C 1-4 alkylene) 0-1 C(O)R a , —(C 1-4 alkylene) 0-1 CO 2 R a , —(C 1-4 alkylene) 0-1 S(O)R a , —(C 1-4 alkylene) 0-1 SO 2 R a , —C(O)NH(R a ), —C(O)N(R a ) 2 , or —C(O)C(O)NH(R a );
wherein each R a is independently
(1) alkyl, unsubstituted or substituted with one or more R m substituents,
wherein each R m is independently selected from the group consisting of deuterium, hydroxy, —NR b R c , alkoxy, cyano, halo, —C(O)alkyl,
—CO 2 alkyl, —CONR b R c , —S(O)alkyl, —SO 2 alkyl, —SO 2 NR b R c , aryl, heteroaryl, cycloalkyl, heterocycloalkyl, phenoxy, and —O-alkyl-OH;
wherein R b is H or alkyl;
R c is H, alkyl, alkoxyalkyl, haloalkyl, —C(O)alkyl, —CO 2 alkyl, —SO 2 alkyl, —C(O)NH 2 , or C(O)H; and
each aryl, heteroaryl, cycloalkyl, and heterocycloalkyl group within R m is unsubstituted or substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, hydroxy, —NR b R c , alkoxy, haloalkoxy, cyano, halo, oxo, —C(O)alkyl, —CO 2 alkyl, —C(O)-heterocycloalkyl, —CONR b R c , —S(O)alkyl, —SO 2 alkyl, —SO 2 -haloalkyl, —SO 2 NR b R c , aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or two substituents taken together form a fused heteroaryl, cycloalkyl, or heterocycloalkyl ring;
wherein each alkyl or alkoxy is unsubstituted or substituted with phenyl, —NR b R c , heterocycloalkyl, heteroaryl, or —C(O)alkyl; and
each aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is unsubstituted or substituted with alkyl, halo, or —C(O)alkyl;
(2) phenyl, cycloalkyl, heteroaryl, or heterocycloalkyl, each unsubstituted or substituted with one or more R g substituents;
wherein each R g is independently selected from the group consisting of alkyl, haloalkyl, hydroxy, —NR b R c , alkoxy, haloalkoxy, cyano, halo, oxo, —C(O)alkyl, —CO 2 alkyl, —C(O)-heterocycloalkyl, —CONR b R c , —S(O)alkyl, —SO 2 alkyl, —SO 2 -haloalkyl, —SO 2 NR b R c , aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or two R g substituents taken together form a fused phenyl, heteroaryl, cycloalkyl, or heterocycloalkyl ring;
wherein each alkyl or alkoxy is unsubstituted or substituted with —NR b R c , heterocycloalkyl, heteroaryl, or —C(O)alkyl; and
each aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is unsubstituted or substituted with alkyl, halo, —CO 2 alkyl, or —C(O)alkyl; or
(3) —NR x R y ,
wherein R x is H or alkyl; and
R y is H, alkyl, alkoxyalkyl, haloalkyl, —C(O)alkyl, —CO 2 alkyl, or —SO 2 alkyl;
R 2 and R 3 are each independently H or deuterium; and
n is 1 or 2;
or a pharmaceutically acceptable salt thereof,
wherein the process comprises a step of contacting a Compound A:
wherein X is —OH, chloro, or bromo,
with a Compound B:
in the presence of a suitable coupling reagent to give the compound of Formula (I).
2. The process of claim 1 , wherein the suitable coupling reagent is EDCI, HATU, or HOBt.
3. The process of claim 1 , comprising contacting a Compound A with a Compound B in the presence of a suitable base.
4. The process of claim 3 , wherein the suitable base is K 2 CO 3 , Cs 2 CO 3 , a trialkylamine, a sodium alkoxide, or a potassium alkoxide.
5. The process of claim 1 , comprising a step of deprotecting a Compound F:
wherein PG 1 is a suitable nitrogen protecting group,
under suitable conditions to give the Compound B.
6. The process of claim 5 , wherein PG 1 is a Boc or Cbz group.
7. The process of claim 5 , comprising a step of contacting a Compound E:
with a compound selected from the group consisting of R a C(O)Cl, R a S(O) 2 Cl, and R a CO 2 H under suitable conditions to give the Compound F.
8. The process of claim 7 , wherein Compound E is contacted with R a C(O)Cl or R a S(O) 2 Cl in the presence of a base.
9. The process of claim 7 , wherein Compound E is contacted with R a CO 2 H under peptide coupling conditions.
10. The process of claim 7 , comprising a step of deprotecting a Compound D:
wherein PG 2 is a suitable nitrogen protecting group,
under suitable conditions to give the Compound E.
11. The process of claim 10 , wherein PG 1 is a Boc or Cbz group.
12. The process of claim 1 , wherein R is an unsubstituted or substituted 8- or 9-membered heteroaryl.
13. The process of claim 1 , wherein R is a five- or six-membered nitrogen-linked heterocycloalkyl ring fused to an unsubstituted or substituted phenyl or monocyclic heteroaryl.
14. The process of claim 1 , wherein R 1 is —C(O)R a , —CO 2 R a , —S(O)R a , or —SO 2 R a .
15. The process of claim 1 , wherein R a is unsubstituted or substituted alkyl.
16. The process of claim 1 , wherein R a is phenyl, cycloalkyl, heteroaryl, or heterocycloalkyl, each unsubstituted or substituted.
17. The process of claim 1 , wherein both R 2 and R 3 are H.
18. A process of preparing a compound of Formula I:
wherein:
R is (a) an 8-, 9-, or 10-membered bicyclic heteroaryl comprising one heteroatom selected from N, S, and O, and one, two, or three additional N atoms, wherein said bicyclic heteroaryl is unsubstituted or is substituted with one or more substituents selected from the group consisting of deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl, and alkoxy, and wherein one or more N atoms of said bicyclic heteroaryl is optionally an N-oxide; or
(b) a five- or six-membered nitrogen-linked heterocycloalkyl ring fused to a phenyl or monocyclic five- or six-membered heteroaryl, wherein said phenyl or heteroaryl is unsubstituted or is substituted with one or more substituents selected from the group consisting of deuterium, amino, alkylamino, dialkylamino, alkyl, halo, cyano, haloalkyl, hydroxy, hydroxyalkyl, and alkoxy; and
R 1 is H, —(C 1-4 alkylene) 0-1 C(O)R a , —(C 1-4 alkylene) 0-1 CO 2 R a , —(C 1-4 alkylene) 0-1 S(O)R a , —(C 1-4 alkylene) 0-1 SO 2 R a , —C(O)NH(R a ), —C(O)N(R a ) 2 , or —C(O)C(O)NH(R a );
wherein each R a is independently
(1) alkyl, unsubstituted or substituted with one or more R m substituents,
wherein each R m is independently selected from the group consisting of deuterium, hydroxy, —NR b R c , alkoxy, cyano, halo, —C(O)alkyl,
—CO 2 alkyl, —CONR b R c , —S(O)alkyl, —SO 2 alkyl, —SO 2 NR b R c , aryl, heteroaryl, cycloalkyl, heterocycloalkyl, phenoxy, and —O-alkyl-OH;
wherein R b is H or alkyl;
R c is H, alkyl, alkoxyalkyl, haloalkyl, —C(O)alkyl, —CO 2 alkyl, —SO 2 alkyl, —C(O)NH 2 , or C(O)H; and
each aryl, heteroaryl, cycloalkyl, and heterocycloalkyl group within R m is unsubstituted or substituted with one or more substituents independently selected from the group consisting of alkyl, haloalkyl, hydroxy, —NR b R c , alkoxy, haloalkoxy, cyano, halo, oxo, —C(O)alkyl, —CO 2 alkyl, —C(O) -heterocycloalkyl, —CONR b R c , —S(O)alkyl, —SO 2 alkyl, —SO 2 -haloalkyl, —SO 2 NR b R c , aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or two substituents taken together form a fused heteroaryl, cycloalkyl, or heterocycloalkyl ring;
wherein each alkyl or alkoxy is unsubstituted or substituted with phenyl, —NR b R c , heterocycloalkyl, heteroaryl, or —C(O)alkyl; and
each aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is unsubstituted or substituted with alkyl, halo, or —C(O)alkyl;
(2) phenyl, cycloalkyl, heteroaryl, or heterocycloalkyl, each unsubstituted or substituted with one or more R g substituents;
wherein each R g is independently selected from the group consisting of alkyl, haloalkyl, hydroxy, —NR b R c , alkoxy, haloalkoxy, cyano, halo, oxo, —C(O)alkyl, —CO 2 alkyl, —C(O)-heterocycloalkyl, —CONR b R c , —S(O)alkyl, —SO 2 alkyl, —SO 2 -haloalkyl, —SO 2 NR b R c , aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or two R g substituents taken together form a fused phenyl, heteroaryl, cycloalkyl, or heterocycloalkyl ring;
wherein each alkyl or alkoxy is unsubstituted or substituted with —NR b R c , heterocycloalkyl, heteroaryl, or —C(O)alkyl; and
each aryl, heteroaryl, cycloalkyl, and heterocycloalkyl is unsubstituted or substituted with alkyl, halo, —CO 2 alkyl, or —C(O)alkyl; or
(3) —NR x R y ,
wherein R x is H or alkyl; and
R y is H, alkyl, alkoxyalkyl, haloalkyl, —C(O)alkyl, —CO 2 alkyl, or —SO 2 alkyl;
R 2 and R 3 are each independently H or deuterium; and
n is 1 or 2;
or a pharmaceutically acceptable salt thereof,
wherein the process comprises a step of contacting a Compound A:
wherein X is chloro or bromo,
with a Compound B:
in the presence of a suitable base to give the compound of Formula (I).
19. The process of claim 18 , wherein the suitable base is triethylamine, K 2 CO 3 , or Cs 2 CO 3 .